Bioventus Reports Second Quarter Financial Results

* Q2 reported revenue of $153.2 million increased 4% * Q2 GAAP earnings of $0.47 per diluted share compared to the prior-year period earnings of $0.11 per diluted share * Non-GAAP earnings* of $0.22 per diluted share compared to $0.21 per diluted share in the prior-year period * Cash from operations totaled $19.9 million * Company reaffirms revenue, Adjusted Diluted EPS* and cash from operations guidance for the full year 2026 * Company initiates review of strategic alternatives DURHAM, N.C., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today reported financial results for the three and six months ended June 27, 2026.

"Bioventus continued its positive momentum in the second quarter, with solid performance that positions us well for continued success in the second half of the year,” said Rob Claypoole, Bioventus President and Chief Executive Officer." We remain focused on disciplined execution while continuing to invest in our four growth drivers. We believe this compelling combination will accelerate revenue growth, strengthen profitability and earnings power, and drive significant free cash flow."